About
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology.
Similar securities
Based on sector and market capitalization